Kozak CA, Adamson MC, Buckler CE, Segovia L, Paralkar V, Wistow G (June 1995). "Genomic cloning of mouse MIF (macrophage inhibitory factor) and genetic mapping of the human and mouse expressed gene and nine mouse pseudogenes". Genomics. 27 (3): 405–11. doi:10.1006/geno.1995.1070. PMID7558020.
Al-Abed Y, VanPatten S (January 2011). "MIF as a disease target: ISO-1 as a proof-of-concept therapeutic". Future Medicinal Chemistry. 3 (1): 45–63. doi:10.4155/fmc.10.281. PMID21428825.
Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, Yang J (February 2010). "Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats". Pain. 148 (2): 275–83. doi:10.1016/j.pain.2009.11.011. PMID20005040. S2CID38141283.
Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. (November 2000). "Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1". Nature. 408 (6809): 211–6. Bibcode:2000Natur.408..211K. doi:10.1038/35041591. PMID11089976. S2CID205010648.
Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (April 2002). "Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease". Microbes and Infection. 4 (4): 449–60. doi:10.1016/S1286-4579(02)01560-5. PMID11932196.
Bloom J, Sun S, Al-Abed Y (December 2016). "MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development". Expert Opinion on Therapeutic Targets. 20 (12): 1463–1475. doi:10.1080/14728222.2016.1251582. PMID27762152. S2CID36752674.
Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. (November 2000). "Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1". Nature. 408 (6809): 211–6. Bibcode:2000Natur.408..211K. doi:10.1038/35041591. PMID11089976. S2CID205010648.
Kozak CA, Adamson MC, Buckler CE, Segovia L, Paralkar V, Wistow G (June 1995). "Genomic cloning of mouse MIF (macrophage inhibitory factor) and genetic mapping of the human and mouse expressed gene and nine mouse pseudogenes". Genomics. 27 (3): 405–11. doi:10.1006/geno.1995.1070. PMID7558020.
Al-Abed Y, VanPatten S (January 2011). "MIF as a disease target: ISO-1 as a proof-of-concept therapeutic". Future Medicinal Chemistry. 3 (1): 45–63. doi:10.4155/fmc.10.281. PMID21428825.
Shan ZX, Lin QX, Deng CY, Tan HH, Kuang SJ, Xiao DZ, et al. (December 2009). "[Identification of the interactions between the truncated fragments of macrophage migration inhibitory factor and CD74 using a yeast two-hybrid system]". Nan Fang Yi Ke da Xue Xue Bao = Journal of Southern Medical University (in Chinese). 29 (12): 2383–6, 2390. PMID20034881.
Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, Yang J (February 2010). "Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats". Pain. 148 (2): 275–83. doi:10.1016/j.pain.2009.11.011. PMID20005040. S2CID38141283.
Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. (November 2000). "Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1". Nature. 408 (6809): 211–6. Bibcode:2000Natur.408..211K. doi:10.1038/35041591. PMID11089976. S2CID205010648.
Lue H, Kleemann R, Calandra T, Roger T, Bernhagen J (April 2002). "Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease". Microbes and Infection. 4 (4): 449–60. doi:10.1016/S1286-4579(02)01560-5. PMID11932196.
Bloom J, Sun S, Al-Abed Y (December 2016). "MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development". Expert Opinion on Therapeutic Targets. 20 (12): 1463–1475. doi:10.1080/14728222.2016.1251582. PMID27762152. S2CID36752674.
Günther S, Fagone P, Jalce G, Atanasov AG, Guignabert C, Nicoletti F (February 2019). "Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets". Drug Discovery Today. 24 (2): 428–439. doi:10.1016/j.drudis.2018.11.003. PMID30439447. S2CID53562815.
Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. (October 1993). "MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia". Nature. 365 (6448): 756–9. Bibcode:1993Natur.365..756B. doi:10.1038/365756a0. PMID8413654. S2CID4321353.
Wang F, Shen X, Guo X, Peng Y, Liu Y, Xu S, Yang J (February 2010). "Spinal macrophage migration inhibitory factor contributes to the pathogenesis of inflammatory hyperalgesia in rats". Pain. 148 (2): 275–83. doi:10.1016/j.pain.2009.11.011. PMID20005040. S2CID38141283.
Kleemann R, Hausser A, Geiger G, Mischke R, Burger-Kentischer A, Flieger O, et al. (November 2000). "Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1". Nature. 408 (6809): 211–6. Bibcode:2000Natur.408..211K. doi:10.1038/35041591. PMID11089976. S2CID205010648.
Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, Momcilovic M, Popadic D, Harhaji L, et al. (June 2008). "Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus". Journal of Cellular Physiology. 215 (3): 665–75. doi:10.1002/jcp.21346. PMID18064633. S2CID36047003.
Bloom J, Sun S, Al-Abed Y (December 2016). "MIF, a controversial cytokine: a review of structural features, challenges, and opportunities for drug development". Expert Opinion on Therapeutic Targets. 20 (12): 1463–1475. doi:10.1080/14728222.2016.1251582. PMID27762152. S2CID36752674.